Pilot Test of a Community-based Buprenorphine Treatment Intervention

This study is currently recruiting participants.
Verified January 2013 by Albert Einstein College of Medicine of Yeshiva University
Sponsor:
Collaborators:
The City University of New York
Washington Heights Corner Project
Information provided by (Responsible Party):
Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier:
NCT01761110
First received: January 2, 2013
Last updated: NA
Last verified: January 2013
History: No changes posted

January 2, 2013
January 2, 2013
December 2012
February 2014   (final data collection date for primary outcome measure)
initiation of buprenorphine treatment [ Time Frame: 60 days ] [ Designated as safety issue: No ]
Medical record information will be extracted to determine initiation of buprenorphine treatment, which will be defined as a visit with a medical provider in which buprenorphine is prescribed.
Same as current
No Changes Posted
opioid use [ Time Frame: 60 days ] [ Designated as safety issue: No ]
Opioid use will be determined via self-report using the Addiction Severity Index and via urine specimens (e.g., urine toxicology testing).
Same as current
HIV risk behaviors [ Time Frame: 60 days ] [ Designated as safety issue: No ]
Drug- and sex-related HIV risk behaviors will be assessed using a standardized risk assessment tool used in NIDA's Clinical Trials Network.
Same as current
 
Pilot Test of a Community-based Buprenorphine Treatment Intervention
Development of a Community-based Buprenorphine Treatment Intervention

The main goal of this study is to pilot test the community-based buprenorphine treatment (CBBT) intervention, examining buprenorphine treatment initiation, opioid use, and HIV risk behaviors. Two groups of participants will be followed for 60 days, with 3 research visits. One group will be enrolled prior to the CBBT intervention (pre-intervention), and one group after the CBBT intervention (post-intervention). Data sources will include questionnaires, urine toxicology tests, and medical record data. We hypothesize that compared to the participants in the pre-intervention group, participants in the post-intervention group will be more likely to initiate buprenorphine treatment, reduce opioid use, and reduce high-risk HIV risk behaviors.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Opioid Dependence
  • Injection Drug Use
Behavioral: Community-based buprenorphine treatment (CBBT) intervention
Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
  • No Intervention: Pre-intervention
    Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
  • Experimental: Post-intervention
    Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
    Intervention: Behavioral: Community-based buprenorphine treatment (CBBT) intervention
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
80
February 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • at least 18 years old
  • English or Spanish fluency
  • ever injected drugs
  • not receiving buprenorphine treatment (no prescribed buprenorphine in the previous 6 months)
  • clients of our collaborating community-based organization
  • interested in buprenorphine treatment

Exclusion Criteria:

  • pregnant
  • taking more than 60mg of methadone daily in the previous 30 days
Both
18 Years and older
No
Contact: Chinazo Cunningham, MD.MS 718-944-3860 ccunning@montefiore.org
Contact: Mia Brisbane, MPH 718-944-3840 mbrisban@montefiore.org
United States
 
NCT01761110
R34DA031066
No
Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University
  • National Institute on Drug Abuse (NIDA)
  • The City University of New York
  • Washington Heights Corner Project
Principal Investigator: Chinazo Cunningham, MD, MS Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP